Showing 3431-3440 of 5257 results for "".
- Review: No Safety Concerns for Live Vaccines with Dupilumabhttps://practicaldermatology.com/news/systematic-review-no-safety-concerns-live-vaccines-dupilumab/2467944/Live vaccines are likely safe and effective for patients undergoing dupilumab treatment, according to results from a systematic review and expert consensus. Authors for a new systematic review, combined with expert input from a Delphi panel, provided insights into the safety and efficacy o
- Timber Pharmaceuticals Fails Phase 3 Trial for Congenital Ichthyosis Drug Candidatehttps://practicaldermatology.com/news/timber-pharmaceuticals-fails-phase-3-trial-congenital-ichthyosis-drug-candidate/2467911/LEO Pharma's subsidiary, Timber Pharmaceuticals, failed a late-stage trial for its investigational topical ointment formulation of isotretinoin for treating moderate to severe congenital ichthyosis. The phase 3 ASCEND trial was 12-week randomized, double-blind clinical study evaluating TM
- Topical Skin Introduces Hydrating Facial Cleanserhttps://practicaldermatology.com/news/topical-skin-introduces-hydrating-facial-cleanser/2467858/Topical Skin announced the launch of the Hydrating Facial Cleanser, formulated with ceramide, botanicals, and oleosomes and designed to provide a gentle yet effective cleanse while supporting the skin's barrier, resulting in a hydrated and refreshed complexion. Unlike some cleansers that
- Panel IDs Key Skincare Strategies for Adult Acnehttps://practicaldermatology.com/news/dermatologists-identify-key-skincare-strategies-adult-acne/2467834/New research featuring input from an expert acne panel emphasized the critical importance of skin care in managing adult acne. The panel, consisting of eight dermatologists, looked at the role of skin barrier function in adult acne and the benefits of adjunctive skin care, such as cleanse
- Survey: Mixed Sentiments for AI in Dermatologyhttps://practicaldermatology.com/news/ai-dermatology-survey-reveals-mixed-sentiments/2467817/A national survey of U.S. dermatologists reveals both enthusiasm and concern about the potential integration of artificial intelligence chatbots (AIC) into dermatological practice. The study, published in the Journal of Drugs in Dermatology, evaluated results from an online cross-sectiona
- Study: LTX-315 Shows 86% Reduction in BCC Tumor Sizehttps://practicaldermatology.com/news/study-ltx-315-shows-86-reduction-bcc-tumor-size/2467796/Lytix Biopharma has announced promising preliminary results from a phase 2 clinical trial evaluating the efficacy of LTX-315, its candidate drug for the treatment of basal cell carcinoma (BCC). The trial was conducted by Verrica Pharmaceuticals, according to a news release, and the result
- New Plasma Proteins Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/new-plasma-proteins-linked-atopic-dermatitis-risk/2467771/New research has identified eight plasma proteins associated with atopic dermatitis (AD), potentially opening new avenues for treatment. Publishing in the Archives of Dermatological Research, the study authors used summary-data-based Mendelian Randomization (SMR) and evaluated dat
- Dietary Sodium Intake Linked to Increased Atopic Dermatitis Riskhttps://practicaldermatology.com/news/dietary-sodium-intake-linked-increased-atopic-dermatitis-risk/2467760/Higher dietary sodium intake has been associated with an increased risk and severity of atopic dermatitis (AD), according to new research in JAMA Dermatology. Researchers for the cross-sectional analysis examined 215,832 participants aged 37-73 years from a UK Biobank cohort using 24-hour
- Five-Year Study Validates Dupilumab for Atopic Dermatitis Managementhttps://practicaldermatology.com/news/five-year-study-validates-dupilumab-atopic-dermatitis-management/2467714/New research has provided evidence of benefit from a long-term strategy of dupilumab for the treatment of atopic dermatitis (AD). Researchers for the multicenter cohort study looked at clinical effectiveness, response times, and reasons for discontinuation of dupilumab treatment over a pe
- Consensus Statement: New Reporting Measures Aim to Improve CSCC Researchhttps://practicaldermatology.com/news/consensus-statement-new-reporting-measures-aim-improve-cscc-research/2467669/A new consensus statement from an expert panel supports the creation of standardized guidelines for retrospective studies on cutaneous squamous cell carcinoma (CSCC). "Despite this morbidity, CSCC is excluded from national cancer registries, making it difficult to study its epidemiology a